Anti‐thymocyte globulin in immune‐mediated cytopenias: A monocentric experience and literature review
Anti-thymocyte globulin in multi-refractory immune-mediated cytopenia is an effective treatment, with response rate as high as 65%. Younger patients, presenting with thrombocytopenia or neutropenia, and those with LGL and STAT3 mutations appear to be more likely responsive.
Authors
- Luca Guarnera (ORCID: https://orcid.org/0000-0001-8293-0663)
- Carlos Bravo‐Pérez (ORCID: https://orcid.org/0000-0001-9794-7847)
- Matteo D’Addona (ORCID: https://orcid.org/0000-0002-1584-1780)
- Christopher Haddad
- Valeria Visconte (ORCID: https://orcid.org/0000-0002-2993-1509)
- Arooj Ahmed
- Olisaemeka Ogbue (ORCID: https://orcid.org/0000-0001-9614-6626)
- Carmelo Gurnari (ORCID: https://orcid.org/0000-0001-6829-5544)
- Arda Durmaz (ORCID: https://orcid.org/0000-0001-8394-600X)
- Aashray Mandala
- Serhan Ünlü (ORCID: https://orcid.org/0000-0002-0425-5030)
- Jaroslaw Pawel Maciejewski (ORCID: https://orcid.org/0000-0002-6837-4346)
- Zachary Brady
Institutions
- University of Rome Tor Vergata (IT)
- Cleveland Clinic (US)
- Instituto de Salud Carlos III (ES)
- Hospital General Universitario Morales Meseguer (ES)
- Centre for Biomedical Network Research on Rare Diseases (ES)
- Universidad de Murcia (ES)
Publication Details
- Journal
- British Journal of Haematology
- Published
- 2025-06-12
- DOI
- https://doi.org/10.1111/bjh.20165
- Primary Topic
- Blood disorders and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Aplastic Anemia and MDS International Foundation
- Edward P. Evans Foundation
- Instituto de Salud Carlos III